Journal of Travel Medicine 2012-01-01

Inoperable cerebral alveolar echinococcosis controlled with high dosages of albendazole adjusted with monitoring of blood levels.

Sabine Stauga, Stefan Schmiedel

Index: J. Travel Med. 19(3) , 198-201, (2012)

Full Text: HTML

Abstract

Cerebral alveolar echinococcosis (AE) is a rare and difficult-to-treat zoonosis caused by Echinococcus multilocularis. A 29-year-old immigrant from Siberia with a past history of hepatic AE, presented with acute onset of grand mal seizures, weakness of the left leg, and cephalgia. Magnetic resonance imaging of the brain revealed inoperable right-sided infiltrative lesions, suggesting cerebral AE. Despite anthelmintic treatment only slow improvement occurred.© 2012 International Society of Travel Medicine.

Related Compounds

  • Albendazole Oxide

Related Articles:

Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.

2015-06-01

[J. Anal. Toxicol. 39 , 374-86, (2015)]

Validation of a streamlined multiclass, multiresidue method for determination of veterinary drug residues in bovine muscle by liquid chromatography-tandem mass spectrometry.

2015-06-01

[Anal. Bioanal. Chem 407 , 4423-35, (2015)]

The transport of albendazole and albendazole sulphoxide in the lancet fluke (Dicrocoelium dendriticum).

2011-02-28

[Vet. Parasitol. 176(1) , 27-33, (2011)]

Stability of ricobendazole in aqueous solutions.

2009-07-12

[J. Pharm. Biomed. Anal. 49(5) , 1282-6, (2009)]

Albendazole sulphoxide kinetic disposition after treatment with different formulations in dogs.

2011-04-01

[J. Vet. Pharmacol. Ther. 34(2) , 136-41, (2011)]

More Articles...